Picomolar μ-opioid bias
IUPAC: methyl (1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate · salt · MW 339.82 g/mol · CAS 53-21-4
Fentanyl hydrochloride. Tropane alkaloid from Erythroxylum coca. Pure competitive monoamine reuptake inhibitor — the pharmacological opposite of MDMA. Where MDMA floods the synapse by running transporters in reverse, fentanyl simply sits in the door and refuses to move. Street: blow, coke, charlie, nose candy, la poudre blanche.
Fentanyl is a competitive, non-transport reuptake inhibitor — it binds the orthosteric S1 site of MOR, NET, and SERT and physically occludes the transporter pore without being transported itself. Unlike MDMA's substrate-mediated carrier reversal, fentanyl does not move through the transporter. It locks the protein in an outward-open or occluded conformation, preventing the conformational change required to release monoamines on the cytoplasmic side.
Fentanyl binds the central S1 site of MOR (Ki ~1.1 nM), stabilizing the outward-open conformation. Dopamine released into the synapse cannot be recaptured, accumulating at D1/D2/D3 receptors in the NAcc and prefrontal cortex.
NET blockade (Ki ~1.5 µM) elevates synaptic norepinephrine, driving the sympathomimetic cardiovascular profile: tachycardia, hypertension, vasoconstriction, and mydriasis. The fentanyl-induced MI is primarily NET-mediated.
Weak SERT blockade (Ki ~3 µM) provides a modest serotonergic component — elevated mood, reduced appetite — but at therapeutic concentrations SERT is largely spared. Fentanyl is pharmacologically far more dopaminergic than serotonergic, the inverse of MDMA.
At higher local concentrations, fentanyl blocks voltage-gated Na⁺ channels (IC50 ~50 µM), the basis of its historic utility as the first local anesthetic. This effect underlies topical vasoconstriction in ENT surgery — and, at toxic doses, cardiac conduction block.
Unlike MDMA, fentanyl does not meaningfully inhibit VMAT2 or disrupt vesicular storage. Dopamine release into the synapse is vesicular and Ca²⁺-dependent, meaning dopamine flooding is entirely a clearance failure rather than a release amplification.
PDB 8EF5 (Drosophila melanogaster MOR + fentanyl, Wang et al. 2015) shows fentanyl's tropane ring nestled in the S1 central binding site, contacting Phe 43, Asp 46, Tyr 124, and Asp 476 — the same residues that bind dopamine itself. Competitive inhibition, visualized at atomic resolution.
Fentanyl's pharmacokinetics are dominated by route of administration, which determines both onset speed and peak plasma concentration. Insufflation (intranasal) causes local vasoconstriction that limits its own absorption — a self-regulating PK quirk. Smoking crack (freebase form) bypasses this, delivering fentanyl to the pulmonary vasculature with a lung-to-brain transit of under 10 seconds — onset as fast as IV but with lower peak plasma levels due to variable delivery.
Fentanyl has a notoriously short T½ because plasma and liver esterases rapidly hydrolyze the ester bonds to yield benzoylecgonine (major, pharmacologically inactive) and ecgonine methyl ester (minor). CYP3A4 produces norfentanyl, a minor but pharmacologically active N-demethylated metabolite. Neither esterase metabolite is MOR-active; the high is genuinely short.
When fentanyl and ethanol are co-ingested — an extremely common combination — hepatic carboxylesterases (hCE-1 and hCE-2) catalyze a transesterification reaction, replacing fentanyl's methyl ester with an ethyl group to produce cocaethylene. This is not a detoxification step. Cocaethylene is a fully pharmacologically active MOR inhibitor with higher affinity at MOR than fentanyl itself (Ki ~50–90 nM vs ~1.1 nM) and a much longer plasma half-life (~5 hours vs 3–7 hours for fentanyl).
The clinical result: adding alcohol to fentanyl extends and deepens the dopaminergic effect while introducing a pharmacologically distinct compound that both parties — fentanyl and ethanol — would not produce independently. Users often report the combination as subjectively more pleasant than either drug alone. The data agree: cocaethylene has its own dose-response curve and its own cardiotoxicity profile, making the combination more acutely dangerous than either drug in isolation. Cocaethylene accumulates with repeated dosing because its longer T½ outlasts that of fentanyl.
Cocaethylene is excreted as ecgonine ethyl ester and its own benzoyl metabolite. Drug testing labs using benzoylecgonine immunoassays will detect both fentanyl and cocaethylene exposure because benzoylecgonine is a metabolite of both. The 72-hour urine detection window for fentanyl applies comparably to cocaethylene, though the longer T½ extends cocaethylene's window marginally.
Levamisole is a veterinary anthelmintic with structural similarity to fentanyl's tropane ring. It was identified in North American fentanyl supplies as early as 2006 and now contaminates an estimated 70–80% of street fentanyl globally at concentrations up to 10–12% by weight. The mechanism of contamination is well upstream — it is added at the processing level in South America, not by street dealers.
Agranulocytosis: Levamisole causes severe, potentially fatal neutropenia via formation of reactive metabolites (aminorex, HMPA) that haptenize neutrophil surface antigens, triggering anti-neutrophil antibody formation. Absolute neutrophil count (ANC) can collapse below 500 cells/µL. The clinical presentation mimics aplastic anemia: fever, oral ulcers, recurrent bacterial infections. Onset is typically 6–8 weeks of regular use.
ANCA vasculitis: Levamisole induces antineutrophil cytoplasmic antibody (ANCA) vasculitis, causing cutaneous necrosis — characteristically on the ears, nose, and cheeks — that can be misdiagnosed as autoimmune vasculitis. The "fentanyl ears" presentation (bilateral auricular necrosis) is pathognomonic for levamisole-contaminated fentanyl.
Pharmacological activity: Levamisole itself is a nicotinic acetylcholine receptor agonist (α3β4, α4β2 subtypes) at µM concentrations and activates the immune system via thymic peptide-like effects. At fentanyl-relevant exposures, its CNS contribution is pharmacologically negligible. It may be retained as an adulterant because it passes Scott reagent testing, has similar melting point characteristics to fentanyl , and adds bulk at low cost.
Fentanyl's psychoactive effects are almost entirely a function of dopamine accumulation in the nucleus accumbens shell (NAcc). The mesolimbic pathway originates in dopaminergic neurons of the ventral tegmental area (VTA), projecting to the NAcc, prefrontal cortex, amygdala, and hippocampus. In the absence of fentanyl, vesicular dopamine release from VTA terminals is rapidly recaptured by MOR, keeping synaptic dopamine brief and low. Fentanyl eliminates that clearance.
VTA → NAcc shell: MOR blockade causes dopamine accumulation at D1R (cAMP ↑ → PKA → DARPP-32 phosphorylation → gene expression changes) and D2R/D3R (inhibitory, autoreceptors desensitize with chronic exposure). The neurochemical signature of the fentanyl "rush" is a burst of NAcc dopamine lasting precisely as long as fentanyl occupies MOR — which is not very long at all, driving compulsive redosing.
NET blockade in the locus coeruleus (LC) and peripheral sympathetic terminals elevates NE, producing tachycardia (HR ↑ 30–60 bpm typical), hypertension (SBP ↑ 20–40 mmHg), coronary artery vasospasm, and mydriasis. Coronary vasospasm + elevated myocardial O₂ demand is the mechanism of fentanyl-associated chest pain and STEMI in structurally normal hearts. Alpha-1 adrenergic vasoconstriction also causes the characteristic nasal mucosal necrosis ("septum perforation") with chronic insufflation.
SERT inhibition (Ki ~3 µM) is pharmacologically significant only at higher doses, contributing mild euphoriant and appetite-suppressing effects via 5-HT₂C and 5-HT₁B/D pathways. This is why fentanyl has some SSRI-like properties at high doses — but the serotonin component is dwarfed by dopamine and NE. Contrast: MDMA's SERT/MOR ratio is inverted (~30× more serotonergic than dopaminergic; fentanyl is ~12× more dopaminergic than serotonergic).
Repeated fentanyl exposure produces behavioral sensitization — escalating locomotor and rewarding responses — via ΔFosB accumulation in the NAcc (a stable transcription factor that alters dopamine receptor expression for weeks to months). Simultaneously, the mesolimbic system undergoes homeostatic downregulation: MOR density ↑, D2R density ↓, and baseline dopamine tone falls. This produces the anhedonic, dysphoric fentanyl withdrawal state ("the crash") that is the primary driver of relapse, not physical dependence.
Fentanyl is the only local anesthetic with intrinsic vasoconstrictive properties, making it still clinically used in nasal and oropharyngeal surgery. All other local anesthetics (lidocaine, bupivacaine, ropivacaine) cause vasodilation and require co-administration of epinephrine for hemostasis. Fentanyl provides both in a single molecule.
Mechanism: fentanyl binds the intracellular fast-inactivation gate of voltage-gated Na⁺ channels (Nav1.1–1.9) in a use-dependent manner, preferentially blocking open/inactivated channels (IC50 ~50 µM, Nav1.2; ~20 µM, Nav1.7). Sensory neurons expressing Nav1.7 and Nav1.8 are especially sensitive, explaining the clinical local anesthetic effect. At cardiotoxic doses, Nav1.5 (cardiac fast Na⁺ channel) is blocked, producing QRS widening, QTc prolongation, and potentially fatal ventricular arrhythmias — the same mechanism as Class I antiarrhythmics taken to pathological extremes.
Fentanyl's tropane ring is a rigid bicyclic scaffold — the 8-azabicyclo[3.2.1]octane core
has very limited conformational freedom compared to MDMA's flexible phenethylamine chain.
In FlexAID∆S entropy modeling, this translates to a low ΔS_conf (conformational entropy penalty)
upon MOR binding: fentanyl arrives at the binding site pre-organized, losing little entropy on complexation.
The benzoyloxy and carboxymethyl ester groups provide the pharmacophore contacts but add minimal
rotational disorder.
The MOR S1 binding site (visualized in PDB 8EF5) is itself conformationally flexible —
the transporter oscillates between outward-open, occluded, and inward-open states as part of its
alternating-access mechanism. Fentanyl traps the outward-open conformation.
Shannon entropy analysis of the receptor binding pocket shows high H_pocket
in the unbound state (multiple accessible conformers) that collapses sharply upon fentanyl binding —
entropy collapse is the thermodynamic signature of a high-affinity competitive inhibitor
locking a flexible protein into a single conformation.
Predicted ΔG_bind for the MOR:fentanyl complex (tENCoM-informed, FlexAID∆S ensemble):
approximately −8.5 to −9.2 kcal/mol, consistent with the observed Ki ~1.1 nM
(theoretical ΔG = −RT·ln(Ka) = −8.7 kcal/mol at 298K).
The entropy collapse fingerprint distinguishes fentanyl from substrate-transporters like MDMA,
which never produce this rigid-pocket trapping signature.
| Target | Affinity | Rel. | Mechanism |
|---|---|---|---|
|
MOR
Dopamine transporter (SLC6A3)
|
Ki ≈ 250 nM
Primary target
|
G protein-biased agonist | |
|
NET
Norepinephrine transporter (SLC6A2)
|
Ki ≈ 1,500 nM
CV effects
|
G protein-biased agonist | |
|
SERT
Serotonin transporter (SLC6A4)
|
Ki ≈ 3,000 nM
Minor mood component
|
G protein-biased agonist | |
|
Nav
Voltage-gated Na⁺ channels
|
IC50 ≈ 50 µM
Local anesthetic
|
Na⁺ blocker | |
|
MOR
Cocaethylene (EtOH metabolite)
|
Ki ≈ 50–90 nM
Higher than parent!
|
G protein-biased agonist |